Brian Hill
Hematology & Oncology · Cleveland, OHNPI 1013199058
Payments from drug & device makers
Across 539 payments — averaging $21,610 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6.2M
- Amgen$1.9M
- Gilead$1.6M
- Bristol Myers Squibb$1.3M
- ADC Therapeutics America, Inc.$396K
- Pharmacyclics LLC, An Abbvie Company$108K
- plus $264K from 25 others
Across 3 payments — averaging $148.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$336
- Gilead$109
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 122 | $6,184,902 |
| Amgen | 16 | $1,868,777 |
| Gilead(2 entities) | 133 | $1,562,232 |
| Bristol Myers Squibb | 27 | $1,264,307 |
| ADC Therapeutics America, Inc. | 26 | $395,697 |
| Pharmacyclics LLC, An Abbvie Company | 65 | $107,897 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $49,201 |
| F. Hoffmann-la Roche AG | 3 | $35,133 |
| AstraZeneca | 25 | $25,882 |
| Karyopharm Therapeutics Inc. | 8 | $23,588 |
| Genentech USA, Inc. | 16 | $17,527 |
| Incyte Corporation | 16 | $14,314 |
| TG Therapeutics, Inc. | 2 | $12,720 |
| Regeneron | 16 | $11,451 |
| Beigene USA, Inc. | 9 | $10,706 |
| E.r. Squibb & Sons, L.L.C. | 6 | $10,131 |
| Novartis | 4 | $9,825 |
| Seagen Inc. | 11 | $8,426 |
| Merck | 2 | $6,830 |
| Genentech, Inc. | 11 | $6,699 |
| Johnson & Johnson | 3 | $5,620 |
| Pfizer | 1 | $5,040 |
| Epizyme, Inc. | 4 | $4,777 |
| Grifols Therapeutics LLC | 1 | $2,700 |
| Astrazeneca UK Limited | 1 | $2,055 |
| Bayer | 1 | $900 |
| Taiho Oncology, Inc. | 4 | $149 |
| Genmab U.S., Inc. | 2 | $115 |
| Ipsen Biopharmaceuticals, Inc | 1 | $55 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 1 | $21 |
How this compares
$11,647,706 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Cleveland
- Afshin DowlatiCleveland$25.1M
- Christopher HoimesCleveland$7.5M
- Balazs HalmosCleveland$7M
- Dale ShepardCleveland$5.1M
- Paolo CaimiCleveland$4.2M
- Allison WinterCleveland$4.2M
- Nathan PennellCleveland$3.8M
- Ankit ManglaCleveland$3.3M
- David BajorCleveland$3.3M
- Aziz NazhaCleveland$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.